INTRODUCTION: The therapeutic arsenal against cutaneous leishmaniasis is very limited. Pentavalent antimonial compounds have been the drugs of choice for treatment of this disease for over 50 years. Despite their effectiveness, these drugs require daily injections, have many side effects and present prolonged healing time. OBJECTIVE: To carry out a systematic literature review on the advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years. METHODS: We conducted an electronic search on the Pubmed and LILACS database as well as on the SciELO electronic library in June 2009. The search words in English were: "cutaneous", "leishmaniasis" and "treatment". We included only randomized, double-blind and placebo controlled trials. We used the Jadad scale to assess the quality of the selected studies. RESULTS: According to the inclusion and exclusion criteria, only eight articles were selected. The drugs evaluated in the selected studies were glucantime®, miltefosine, immunotherapy, imiquimod, rhGM-CSF and pentoxifylline, and paromomycin. CONCLUSION: Although cutaneous leishmaniasis is a major public health issue, the published data on the use of new drugs for the treatment of cutaneous leishmaniasis in Brazil are still quite limited.
INTRODUCTION: The therapeutic arsenal against cutaneous leishmaniasis is very limited. Pentavalent antimonial compounds have been the drugs of choice for treatment of this disease for over 50 years. Despite their effectiveness, these drugs require daily injections, have many side effects and present prolonged healing time. OBJECTIVE: To carry out a systematic literature review on the advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years. METHODS: We conducted an electronic search on the Pubmed and LILACS database as well as on the SciELO electronic library in June 2009. The search words in English were: "cutaneous", "leishmaniasis" and "treatment". We included only randomized, double-blind and placebo controlled trials. We used the Jadad scale to assess the quality of the selected studies. RESULTS: According to the inclusion and exclusion criteria, only eight articles were selected. The drugs evaluated in the selected studies were glucantime®, miltefosine, immunotherapy, imiquimod, rhGM-CSF and pentoxifylline, and paromomycin. CONCLUSION: Although cutaneous leishmaniasis is a major public health issue, the published data on the use of new drugs for the treatment of cutaneous leishmaniasis in Brazil are still quite limited.
Authors: Tatiane F P de Mello; Bruna M Cardoso; Sara N Lopes; Heriberto R Bitencourt; Evandra M Voltarelli; Luzmarina Hernandes; Sandra M A Aristides; Maria V C Lonardoni; Thais G V Silveira Journal: Parasitol Res Date: 2015-06-23 Impact factor: 2.289
Authors: Alejandro Ordaz-Farias; Fania Z Muñoz-Garza; Farah K Sevilla-Gonzalez; Ana Arana-Guajardo; Jorge Ocampo-Candiani; Nancy Treviño-Garza; Ingeborg Becker; Adrian Camacho-Ortiz Journal: Am J Trop Med Hyg Date: 2012-12-12 Impact factor: 2.345
Authors: Kristina M Bacon; Peter J Hotez; Stephanie D Kruchten; Shaden Kamhawi; Maria Elena Bottazzi; Jesus G Valenzuela; Bruce Y Lee Journal: Vaccine Date: 2012-11-20 Impact factor: 3.641
Authors: Márcia dos Santos da Silva; Renato Telles de Sousa; Eucides Batista da Silva; Jorge Augusto de Oliveira Guerra; Nathália Matos Gomes; Renata Farias de Santana; Rebecca Souza Mubarac Journal: Braz J Otorhinolaryngol Date: 2012-10
Authors: Ludovic Reveiz; Ana Nilce Silveira Maia-Elkhoury; Rubén Santiago Nicholls; Gustavo Adolfo Sierra Romero; Zaida E Yadon Journal: PLoS One Date: 2013-04-29 Impact factor: 3.240